Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans

Author(s):
Klumpers, L.E.; Roy, C.; Ferron, G.; Turpault, S.; Poitiers, F.; Pinquier, J.L.; Hasselt, J.G.C. van; Zuurman, L.; Erwich, F.A.S.; Gerven, J.M.A. van (0000-0002-1444-7415)
Published
2013
Publication type
Article / Letter to editor
CB1 receptor antagonistpharmacodynamicspharmacokineticsPK-PD modellingSR147778surinabant
Date issued
2013-07-31
Language
English
Is part of
British Journal of Clinical Pharmacology (2013), Vol. 76, no. 1, p. 65-77
hdl
1887/102436
doi
10.1111/bcp.12071